2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Sell
46
DVA Quote, Financials, Valuation and Earnings
Last price:
$136.27
Seasonality move
:
3%
Day range:
$134.56 - $136.92
52-week range:
$131.76 - $179.60
Dividend yield:
0%
P/E ratio:
13.50x
P/S ratio:
0.89x
P/B ratio:
95.39x
Volume:
1.2M
Avg. volume:
815.1K
1-year change:
-7.39%
Market cap:
$10.3B
Revenue:
$12.8B
EPS (TTM):
$10.09
Analysts' Opinion
-
Consensus RatingDaVita has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $162.92, DaVita has an estimated upside of 19.57% from its current price of $136.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $145.00 representing -6.41% downside risk from its current price of $136.26.
Fair Value
-
According to the consensus of 9 analysts, DaVita has 19.57% upside to fair value with a price target of $162.92 per share.
DVA vs. S&P 500
-
Over the past 5 trading days, DaVita has underperformed the S&P 500 by -3.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
DaVita does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
DaVita has grown year-over-year revenues for 9 quarters straight. In the most recent quarter DaVita reported revenues of $3.2B.
Earnings Growth
-
DaVita earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter DaVita reported earnings per share of $2.00.
Enterprise value:
21.5B
EV / Invested capital:
1.88x
Price / LTM sales:
0.89x
EV / EBIT:
10.99x
EV / Revenue:
1.65x
PEG ratio (5yr expected):
0.92x
EV / Free cash flow:
12.19x
Price / Operating cash flow:
6.58x
Enterprise value / EBITDA:
8.05x
Gross Profit (TTM):
$4.2B
Return On Assets:
4.98%
Net Income Margin (TTM):
6.63%
Return On Equity:
38.96%
Return On Invested Capital:
7.42%
Operating Margin:
13.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $11.7B | $12.3B | $13B | $3.1B | $3.2B | |
| Gross Profit | $3.4B | $4B | $4.2B | $991.6M | $983.9M | |
| Operating Income | $1.3B | $1.7B | $1.9B | $442M | $433.3M | |
| EBITDA | $2B | $2.5B | $2.7B | $658.3M | $597.8M | |
| Diluted EPS | $5.42 | $8.80 | $10.09 | $2.65 | $2.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.9B | $3.1B | $3B | $3.7B | $3.6B | |
| Total Assets | $17.6B | $17.1B | $16.7B | $17.4B | $17.1B | |
| Current Liabilities | $2.3B | $2.4B | $2.6B | $2.6B | $2.9B | |
| Total Liabilities | $14.9B | $14.7B | $14.3B | $14.8B | $15.5B | |
| Total Equity | $2.8B | $2.4B | $2.4B | $2.6B | $1.7B | |
| Total Debt | $9B | $8.9B | $8.7B | $9.1B | $9.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.7B | $1.5B | $2.3B | -$134.8M | $180M | |
| Cash From Investing | -$628.5M | -$870.5M | -$718.4M | -$215.2M | -$162.1M | |
| Cash From Financing | -$1.1B | -$575.3M | -$1.5B | $319.3M | -$382.5M | |
| Free Cash Flow | $1.1B | $920.3M | $1.8B | -$255.9M | $36.8M | |
DVA
Sector
Market Cap
$10.3B
$33.4M
Price % of 52-Week High
75.87%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
11.73%
-0.66%
1-Year Price Total Return
-7.39%
-40%
Beta (5-Year)
1.141
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$139.06
200-day SMA
Sell
Level
$153.74
Bollinger Bands (100)
Sell
Level
139.39 - 163.71
Chaikin Money Flow
Buy
Level
2.5M
20-day SMA
Sell
Level
$141.57
Relative Strength Index (RSI14)
Sell
Level
37.86
ADX Line
Sell
Level
20.12
Williams %R
Buy
Level
-87.0427
50-day SMA
Sell
Level
$144.56
MACD (12, 26)
Buy
Level
1.30
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-4.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.777)
Sell
CA Score
(Annual)
Level (-1.7805)
Buy
Beneish M-Score
(Annual)
Level (-2.6651)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (1.2474)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Stock Forecast FAQ
In the current month, DVA has received 1 Buy ratings 8 Hold ratings, and 0 Sell ratings. The DVA average analyst price target in the past 3 months is $162.92.
-
Where Will DaVita Stock Be In 1 Year?
According to analysts, the consensus estimate is that DaVita share price will rise to $162.92 per share over the next 12 months.
-
What Do Analysts Say About DaVita?
Analysts are divided on their view about DaVita share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DaVita is a Sell and believe this share price will drop from its current level to $145.00.
-
What Is DaVita's Price Target?
The price target for DaVita over the next 1-year time period is forecast to be $162.92 according to 9 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is DVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for DaVita is a Hold. 8 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DVA?
You can purchase shares of DaVita via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DaVita shares.
-
What Is The DaVita Share Price Today?
DaVita was last trading at $136.27 per share. This represents the most recent stock quote for DaVita. Yesterday, DaVita closed at $136.26 per share.
-
How To Buy DaVita Stock Online?
In order to purchase DaVita stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
